Wells Fargo & Company MN Has $15.58 Million Holdings in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Wells Fargo & Company MN lifted its position in Prestige Consumer Healthcare Inc. (NYSE:PBH - Free Report) by 103.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 199,449 shares of the company's stock after purchasing an additional 101,179 shares during the quarter. Wells Fargo & Company MN owned about 0.40% of Prestige Consumer Healthcare worth $15,575,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in PBH. Kestra Investment Management LLC acquired a new position in Prestige Consumer Healthcare during the 4th quarter worth about $27,000. CIBC Private Wealth Group LLC boosted its position in Prestige Consumer Healthcare by 48.9% in the 4th quarter. CIBC Private Wealth Group LLC now owns 463 shares of the company's stock valued at $34,000 after buying an additional 152 shares during the period. Headlands Technologies LLC purchased a new stake in shares of Prestige Consumer Healthcare during the fourth quarter worth $40,000. GAMMA Investing LLC boosted its holdings in Prestige Consumer Healthcare by 18.9% in the fourth quarter. GAMMA Investing LLC now owns 1,383 shares of the company's stock valued at $108,000 after purchasing an additional 220 shares during the period. Finally, Huntington National Bank lifted its position in shares of Prestige Consumer Healthcare by 133.2% during the 4th quarter. Huntington National Bank now owns 1,481 shares of the company's stock worth $116,000 after purchasing an additional 846 shares during the last quarter. 99.95% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, SVP Mary Beth Fritz sold 1,678 shares of Prestige Consumer Healthcare stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $90.00, for a total transaction of $151,020.00. Following the transaction, the senior vice president now directly owns 17,157 shares in the company, valued at approximately $1,544,130. The trade was a 8.91 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 1.60% of the stock is currently owned by company insiders.

Prestige Consumer Healthcare Stock Up 0.4 %

PBH traded up $0.30 on Friday, reaching $80.10. The company's stock had a trading volume of 292,350 shares, compared to its average volume of 286,506. Prestige Consumer Healthcare Inc. has a 1 year low of $62.35 and a 1 year high of $90.04. The business's 50 day moving average is $84.27 and its 200 day moving average is $80.03. The company has a debt-to-equity ratio of 0.56, a current ratio of 3.68 and a quick ratio of 2.20. The stock has a market cap of $3.97 billion, a price-to-earnings ratio of 18.76, a price-to-earnings-growth ratio of 2.69 and a beta of 0.47.

Prestige Consumer Healthcare (NYSE:PBH - Get Free Report) last announced its quarterly earnings data on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.18 by $0.04. Prestige Consumer Healthcare had a return on equity of 12.36% and a net margin of 19.13%. As a group, research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities analysts have commented on the stock. DA Davidson increased their price target on shares of Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a "buy" rating in a research note on Friday, February 7th. Canaccord Genuity Group raised their target price on shares of Prestige Consumer Healthcare from $93.00 to $100.00 and gave the stock a "buy" rating in a research report on Friday, February 7th. Royal Bank of Canada increased their price target on Prestige Consumer Healthcare from $96.00 to $97.00 and gave the stock a "sector perform" rating in a research note on Friday, March 21st. StockNews.com lowered Prestige Consumer Healthcare from a "buy" rating to a "hold" rating in a research note on Tuesday, April 8th. Finally, Raymond James upgraded shares of Prestige Consumer Healthcare to a "moderate buy" rating in a report on Thursday, December 19th. Four equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, Prestige Consumer Healthcare presently has an average rating of "Hold" and a consensus target price of $93.33.

Prestige Consumer Healthcare Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.